Adgero Biopharmaceuticals Holdings Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Adgero Biopharmaceuticals Holdings Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013135
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:34
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Adgero Biopharmaceuticals Holdings Inc (Adgero) is a biopharmaceutical company which advances its proprietary late stage photodynamic therapy (PDT) for the treatment of unmet clinical needs of patients with cutaneous metastatic breast cancer (CMBC) and bile duct cancer. Its PDT is a treatment utilizes light sensitive compounds which act as catalyst to produce a form of oxygen that induces local tumor cell death when exposed to specific wavelengths of light. The company’s lead pipeline candidate, REM-001 therapy, consists of a light delivery device; a laser light source, and the drug REM-001. It is also investigating REM-001 as follow on indication for Cutaneous Metastatic Cancers of Lung, Colon, and Ovary. Adgero is headquartered in Princeton Junction, New Jersey, the US.

Adgero Biopharmaceuticals Holdings Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Adgero Biopharma Acquires Certain Assets and Regulatory Filings from Miravant Medical Technologies 10
Venture Financing 11
Adgero Biopharma Raises USD0.5 Million in Venture Financing 11
Adgero Biopharma Raises USD3 Million Financing 12
Adgero Biopharma Raises Funds through Venture Financing 13
Equity Offering 14
Adgero Biopharma Raises USD3.4 Million in Private Placement of Shares upon Exercise of Warrants 14
Adgero Biopharma Raises USD2 Million in Equity Financing 15
Adgero Biopharma to Raise Funds in Private Placement of Shares and Warrants 16
Adgero Biopharma Raises USD2 Million in Private Placement of Shares 17
Adgero Biopharma Raises USD9.7 Million in Equity Financing 18
Debt Offering 19
Adgero Biopharma Raises USD0.3 Million in Private Placement of 6% Notes Due 2016 19
Adgero Biopharma Raises Funds in Private Placement of 6% Notes Due 2016 20
Adgero Biopharma Raises Funds in Private Placement of 6% Notes Due 2016 21
Adgero Biopharmaceuticals Holdings Inc – Key Competitors 22
Adgero Biopharmaceuticals Holdings Inc – Key Employees 23
Adgero Biopharmaceuticals Holdings Inc – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Corporate Communications 25
Oct 25, 2017: Adgero Biopharmaceuticals Appoints John Liatos as Chief Financial Officer 25
Sep 14, 2017: Adgero Biopharmaceuticals Appoints Felix T. Garzon, M.D., Ph.D. as Chief Medical Officer 26
Feb 14, 2017: Adgero Biopharmaceuticals Holdings, Inc. Expands Executive Management Team with Appointment of Jane M. Maida as Chief Financial Officer 27
Product News 28
09/27/2016: Adgero Biopharmaceuticals to Present at the Fifth Annual OktoberINVESTfest, US – Bavaria, Germany Investors Conference in New York 28
05/03/2016: Adgero Biopharmaceuticals to Present at the Joseph Gunnar Pioneers 2016 Conference 29
01/26/2017: Adgero Biopharmaceuticals to Present at Noble Capital Markets’ Thirteenth Annual Investor Conference 30
01/14/2016: Adgero Biopharmaceuticals to Present at Noble Financial Capital Markets 12th Annual Investor Conference on January 18, 2016 31
01/05/2016: Adgero Biopharmaceuticals to Present at Biotech Showcase on January 11, 2016 32
Clinical Trials 33
Apr 10, 2017: Positive Clinical Data of Adgero Biopharmaceuticals’ REM-001 Therapy for the Treatment of Cutaneous Metastatic Breast Cancer Presented at 37th ASLMS Annual Conference 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Key Facts 2
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Adgero Biopharmaceuticals Holdings Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Adgero Biopharma Acquires Certain Assets and Regulatory Filings from Miravant Medical Technologies 10
Adgero Biopharma Raises USD0.5 Million in Venture Financing 11
Adgero Biopharma Raises USD3 Million Financing 12
Adgero Biopharma Raises Funds through Venture Financing 13
Adgero Biopharma Raises USD3.4 Million in Private Placement of Shares upon Exercise of Warrants 14
Adgero Biopharma Raises USD2 Million in Equity Financing 15
Adgero Biopharma to Raise Funds in Private Placement of Shares and Warrants 16
Adgero Biopharma Raises USD2 Million in Private Placement of Shares 17
Adgero Biopharma Raises USD9.7 Million in Equity Financing 18
Adgero Biopharma Raises USD0.3 Million in Private Placement of 6% Notes Due 2016 19
Adgero Biopharma Raises Funds in Private Placement of 6% Notes Due 2016 20
Adgero Biopharma Raises Funds in Private Placement of 6% Notes Due 2016 21
Adgero Biopharmaceuticals Holdings Inc, Key Competitors 22
Adgero Biopharmaceuticals Holdings Inc, Key Employees 23

★海外企業調査レポート[Adgero Biopharmaceuticals Holdings Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Valora Holding AG (VALN):企業の財務・戦略的SWOT分析
    Valora Holding AG (VALN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Schroders Plc
    Schroders Plc - Strategy, SWOT and Corporate Finance Report Summary Schroders Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • 3M Company:戦略・SWOT・企業財務分析
    3M Company - Strategy, SWOT and Corporate Finance Report Summary 3M Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Brooks MacDonald Group PLC (BRK)
    Brooks MacDonald Group PLC (BRK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • SCSK Corporation:企業の戦略・SWOT・財務分析
    SCSK Corporation - Strategy, SWOT and Corporate Finance Report Summary SCSK Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • PetroEnergy Resources Corp (PERC):企業の財務・戦略的SWOT分析
    Summary PetroEnergy Resources Corp (PERC) is a diversified company that offers oilfield and energy services. The company’s services include upstream oil and gas exploration and development, power generation, and renewable energy development services, among others. It undertakes renewable energy proj …
  • CryoPort Inc (CYRX)-製薬・医療分野:企業M&A・提携分析
    Summary Cryoport Inc (Cryoport) is a provider of cold chain logistics solutions for temperature-sensitive biological materials to the life science industries. It offers liquid nitrogen dry vapor shippers with advanced logistics management platform called Cryoportal, which provides credentials relate …
  • Lotus Pharmaceutical Co Ltd (1795):製薬・医療:M&Aディール及び事業提携情報
    Summary Lotus Pharmaceutical Co Ltd (Lotus Pharmaceutical), a subsidiary of Alvogen Inc is a pharmaceutical company that develops and sells pharmaceutical products. The company provides products that are used in the treatment of rheumatology, cancer, cardiology, dyslipidemia, hypertension, woman hea …
  • B.L. Kashyap and Sons Ltd:企業の戦略・SWOT・財務情報
    B.L. Kashyap and Sons Ltd - Strategy, SWOT and Corporate Finance Report Summary B.L. Kashyap and Sons Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Mphasis Limited:企業の戦略・SWOT・財務分析
    Mphasis Limited - Strategy, SWOT and Corporate Finance Report Summary Mphasis Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • TradeWind Energy-エネルギー分野:企業M&A・提携分析
    Summary TradeWind Energy LLC (TWE) is an alternative energy company that develops wind and solar energy projects. The company purchases physical output from a wind and solar energy project; and offers financial contract services and hedging against rising power costs. Its wind project portfolio incl …
  • Chemring Energetics UK Ltd:企業の戦略・SWOT・財務情報
    Chemring Energetics UK Ltd - Strategy, SWOT and Corporate Finance Report Summary Chemring Energetics UK Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • BioNTech AG:製薬・医療:M&Aディール及び事業提携情報
    Summary BioNTech AG (BioNTech) is a biopharmaceutical company that develops biomarker based diagnostics. The company’s products include RNXtract and mammatyper, and cell and gene therapies. It pipeline products include BioNTech mRNA pharmaceuticals, BioNTech cell and gene, BioNTech small molecules a …
  • CRH Medical Corp (CRH):医療機器:M&Aディール及び事業提携情報
    Summary CRH Medical Corp (CRH Medical), formerly Medsurge Medical Products Corp, is a medical device company that offers treatment of hemorrhoids. The company provides CRH O’Regan System, a hemorrhoid technology for treating hemorrhoid. It offers topical ointments and creams including preparation H …
  • Myriad RBM Inc-医療機器分野:企業M&A・提携分析
    Summary Myriad RBM Inc (Myriad RBM), formerly Rules Based Medicine Inc, a subsidiary of Myriad Genetics Inc, is an immunoassay testing laboratory that provides protein biomarker products and services. The company’s products and services include HumanMAP services that assist investigators in the disc …
  • Vision RT Ltd:企業の戦略的SWOT分析
    Vision RT Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • TransDigm Group Incorporated:企業のM&A・事業提携・投資動向
    TransDigm Group Incorporated - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's TransDigm Group Incorporated Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Wegmans Food Markets, Inc.:企業の戦略・SWOT・財務分析
    Wegmans Food Markets, Inc. - Strategy, SWOT and Corporate Finance Report Summary Wegmans Food Markets, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Murphy Oil Corporation:戦略・SWOT・企業財務分析
    Murphy Oil Corporation - Strategy, SWOT and Corporate Finance Report Summary Murphy Oil Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Synedgen Inc-製薬・医療分野:企業M&A・提携分析
    Summary Synedgen Inc (Synedgen) is a biotechnology company that focuses on the discovery and development of polysaccharide-based drugs. The company’s pipeline products include SYGN 113; SYGN 115; SYGN 146; SYGN 303; SYGN 313 and SYGN 399 among others. Synedgen develops products for the treatment of …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆